With $354,826 in CMTA funding, the SENSE Trial is an HSN1 clinical trial investigating a potential treatment for hereditary sensory neuropathy type 1, with active participation now complete and final data analysis underway.
Simply CMT
More From Simply CMT
-
-
New Clinical Trial Recommendations for CMT Help Speed Therapies to Patients
CMTA is leading efforts to improve CMT clinical trials through new recommendations that help create a clearer path for developing and approving new therapies.